- Home
- BREA vs GOVX Comparison
BREA vs GOVX Comparison
Compare BREA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- GOVX
- Stock Information
- Founded
- BREA 2022
- GOVX 2001
- Country
- BREA Ireland
- GOVX United States
- Employees
- BREA N/A
- GOVX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- GOVX Health Care
- Exchange
- BREA Nasdaq
- GOVX Nasdaq
- Market Cap
- BREA 13.6M
- GOVX 15.5M
- IPO Year
- BREA 2023
- GOVX N/A
- Fundamental
- Price
- BREA $6.88
- GOVX $0.95
- Analyst Decision
- BREA
- GOVX Strong Buy
- Analyst Count
- BREA 0
- GOVX 5
- Target Price
- BREA N/A
- GOVX $12.40
- AVG Volume (30 Days)
- BREA 18.5K
- GOVX 1.5M
- Earning Date
- BREA 01-03-2025
- GOVX 08-05-2025
- Dividend Yield
- BREA N/A
- GOVX N/A
- EPS Growth
- BREA N/A
- GOVX N/A
- EPS
- BREA N/A
- GOVX N/A
- Revenue
- BREA $2,988,009.00
- GOVX $5,591,576.00
- Revenue This Year
- BREA N/A
- GOVX N/A
- Revenue Next Year
- BREA N/A
- GOVX N/A
- P/E Ratio
- BREA N/A
- GOVX N/A
- Revenue Growth
- BREA 151.51
- GOVX N/A
- 52 Week Low
- BREA $5.00
- GOVX $0.73
- 52 Week High
- BREA $19.50
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- BREA 96.66
- GOVX 46.22
- Support Level
- BREA $0.66
- GOVX $0.85
- Resistance Level
- BREA $0.79
- GOVX $1.39
- Average True Range (ATR)
- BREA 0.20
- GOVX 0.15
- MACD
- BREA 0.39
- GOVX -0.02
- Stochastic Oscillator
- BREA 84.50
- GOVX 18.52
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.